{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/irritable-bowel-syndrome/prescribing-information/loperamide/","result":{"pageContext":{"chapter":{"id":"b36ea15d-0d7e-5080-9c77-f7f1b274523b","slug":"loperamide","fullItemName":"Loperamide","depth":2,"htmlHeader":"<!-- begin field 1ff1fe28-8d40-4664-8df7-fa0e72db747d --><h2>Loperamide</h2><!-- end field 1ff1fe28-8d40-4664-8df7-fa0e72db747d -->","summary":"","htmlStringContent":"<!-- begin item f536ad45-f3f8-4e47-b5f7-8d818970ceb8 --><!-- begin field b2b823e4-a755-4809-8808-a80000f8ea14 --><p>Loperamide is licensed for the symptomatic treatment of acute diarrhoea in irritable bowel syndrome (IBS). The recommended dose is:</p><ul><li>Initially 4 mg, followed by 2 mg for up to five days, dose to be taken after each loose stool; usual dose 6–8 mg daily; maximum 16 mg per day.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/irritable-bowel-syndrome/references/\">BNF 73, 2017</a>]</p><!-- end field b2b823e4-a755-4809-8808-a80000f8ea14 --><!-- end item f536ad45-f3f8-4e47-b5f7-8d818970ceb8 -->","topic":{"id":"4bb8acbd-d2b1-5f93-9ffa-0a3f11076292","topicId":"2c2fedc7-3daf-462e-b168-78c86cb2a2ec","topicName":"Irritable bowel syndrome","slug":"irritable-bowel-syndrome","lastRevised":"Last revised in October 2020","chapters":[{"id":"e08d84ab-7283-58cb-9873-bebac62d6494","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"09b06ced-d018-5c24-883c-ff37be197b2d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"14d879ef-e87a-571a-a829-4f236e5265b8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0858c465-429d-5390-b8bd-432cb1d0fb46","slug":"changes","fullItemName":"Changes"},{"id":"fbcab9c4-bcb5-5d61-855f-1ec3aef8fdfe","slug":"update","fullItemName":"Update"}]},{"id":"d1d333cb-5ad0-5c55-987c-0d9bcdd7219b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"df8485dd-d258-554e-91a1-cfae144c8f3a","slug":"goals","fullItemName":"Goals"},{"id":"92f70986-7a29-5aaf-8c2b-e24b675e84dc","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4cbbe159-85f5-573d-a6f1-cf83b24c7513","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b054d7f7-3303-57ad-bc98-df229e629e9c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d5eb318d-cbd0-556b-8ce7-6c20aab02bc0","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c7ecf3c9-b183-5b40-99b8-9fa4ac12bfb8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"156f0f16-df4f-5fcf-94da-2e9dfe0d9ae7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d091ffcd-a585-5def-b8a6-6a8e82be964d","slug":"definition","fullItemName":"Definition"},{"id":"08e0e6c7-a53c-53d9-a8ff-37b9af0475a9","slug":"causes","fullItemName":"Causes"},{"id":"2af080fe-338c-5682-927e-df91b2056310","slug":"prevalence","fullItemName":"Prevalence"},{"id":"668a8344-5367-57b6-be24-4904a8b84c09","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"d71af51f-0d21-583c-ae74-cdeefe5efe9a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1e13d165-63d9-5000-8411-3cb047828b3a","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"d335e933-3ba3-56d3-9f86-ccb100e2cb09","slug":"assessment","fullItemName":"Assessment"},{"id":"f6a63ea2-fb31-5f4c-b6ca-21ee922d5615","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"a0f45b9c-efa3-5c88-a5bc-3cd26c71883f","fullItemName":"Management","slug":"management","subChapters":[{"id":"d4748fe8-65f9-5b0b-bbd0-32469fde1c78","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"86d862ff-43f3-59ac-9769-c4bc0ec5ea9b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4517eb7c-ad75-5732-86b2-ea7cf18e7a93","slug":"bulk-forming-laxatives","fullItemName":"Bulk-forming laxatives"},{"id":"712646a9-5a89-5454-b98e-b2d2dce9ac3d","slug":"linaclotide","fullItemName":"Linaclotide"},{"id":"b36ea15d-0d7e-5080-9c77-f7f1b274523b","slug":"loperamide","fullItemName":"Loperamide"},{"id":"c7ea4d4a-3d5a-5cdb-8999-e01670699563","slug":"antispasmodic-drugs","fullItemName":"Antispasmodic drugs"},{"id":"b5eff265-676e-584f-a5d6-0a4714238d8f","slug":"antidepressant-drugs","fullItemName":"Antidepressant drugs"}]},{"id":"2c06aa30-84a6-5e94-8d6f-1d960d28dcdc","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"25c14e40-3957-5b26-aa34-0afc73225fdd","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"38e74c6b-daec-50bd-a23a-3aa30b83db82","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c6497438-25eb-590a-9d9d-dfe08a17fb21","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"36885cba-cf5e-5cab-a474-2c0fc504fa91","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"89b5e4f9-0ed1-5b13-8258-3ba2b6f5b43e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d3199940-6be9-57b4-a2b0-2ee240db6d97","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5667ce2f-151b-57f5-9fde-07b6339b1aef","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"86d862ff-43f3-59ac-9769-c4bc0ec5ea9b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"bcdf0ed2-43bf-5529-ab34-962076a329a6","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 352e5bbb-ec6a-494b-981f-0d162801aec1 --><h3>Contraindications and cautions</h3><!-- end field 352e5bbb-ec6a-494b-981f-0d162801aec1 -->","summary":"","htmlStringContent":"<!-- begin item fcf778ef-1ba4-4871-a8e0-170b3965ce89 --><!-- begin field ff60d0e9-9865-4205-a2bc-2bcc774cfcb7 --><p><strong>Do not prescribe loperamide if the person has:</strong></p><ul><li>Acute ulcerative colitis.</li><li>Antibiotic-associated colitis.</li><li>Conditions where abdominal distention develops.</li><li>Conditions where inhibition of peristalsis should be avoided.</li></ul><p><strong>Prescribe loperamide with caution if the person has:</strong></p><ul><li>Hepatic impairment — due to reduced first-pass metabolism and the risk of hepatic accumulation.</li><li>A history of drug abuse.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/irritable-bowel-syndrome/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/irritable-bowel-syndrome/references/\">ABPI, 2020a</a>]</p><!-- end field ff60d0e9-9865-4205-a2bc-2bcc774cfcb7 --><!-- end item fcf778ef-1ba4-4871-a8e0-170b3965ce89 -->","subChapters":[]},{"id":"90b008f3-9f78-5755-a345-45eedb234fe3","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 6190c643-c04f-4b24-8eb2-319235c5cb85 --><h3>Adverse effects</h3><!-- end field 6190c643-c04f-4b24-8eb2-319235c5cb85 -->","summary":"","htmlStringContent":"<!-- begin item f6720445-7381-4a00-b530-accc81ebe781 --><!-- begin field bfe213bf-a0b7-4187-8d86-2b4bcd5c5635 --><p><strong>Possible adverse effects of loperamide include:</strong></p><ul><li>Dizziness, headaches, flatulence, nausea.</li><li>Abdominal pain, drowsiness, dry mouth, dyspepsia, rash, vomiting.</li><li>Note: advise the person not to exceed the recommended dose or duration of treatment, as cardiac events including QT interval prolongation, Brugada syndrome, and torsades de pointes arrhythmia have been reported in association with overdose.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/irritable-bowel-syndrome/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/irritable-bowel-syndrome/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/irritable-bowel-syndrome/references/\">ABPI, 2020b</a>] </p><!-- end field bfe213bf-a0b7-4187-8d86-2b4bcd5c5635 --><!-- end item f6720445-7381-4a00-b530-accc81ebe781 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}